XVIVO logo

Xvivo Perfusion AB (publ) Stock Price

OM:XVIVO Community·SEK 5.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

XVIVO Share Price Performance

SEK 164.90
-316.10 (-65.72%)
52.3% undervalued intrinsic discount
SEK 345.60
Fair Value
SEK 164.90
-316.10 (-65.72%)
53.5% undervalued intrinsic discount
SEK 355.00
Fair Value
Price SEK 164.90
AnalystConsensusTarget SEK 355.00

XVIVO Community Narratives

AnalystConsensusTarget·Updated
Fair Value SEK 345.6 52.3% undervalued intrinsic discount

DELIVER IDE Approvals And US Trials Will Unlock New Markets

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative

Recent XVIVO News & Updates

These Analysts Just Made A Massive Downgrade To Their Xvivo Perfusion AB (publ) (STO:XVIVO) EPS Forecasts

Jul 17
These Analysts Just Made A Massive Downgrade To Their Xvivo Perfusion AB (publ) (STO:XVIVO) EPS Forecasts

Earnings Miss: Xvivo Perfusion AB (publ) Missed EPS And Analysts Are Revising Their Forecasts

Jul 14
Earnings Miss: Xvivo Perfusion AB (publ) Missed EPS And Analysts Are Revising Their Forecasts

Xvivo Perfusion AB (publ)'s (STO:XVIVO) 37% Cheaper Price Remains In Tune With Earnings

Jul 12
Xvivo Perfusion AB (publ)'s (STO:XVIVO) 37% Cheaper Price Remains In Tune With Earnings

Xvivo Perfusion AB (publ) Key Details

SEK 822.9m

Revenue

SEK 206.8m

Cost of Revenue

SEK 616.1m

Gross Profit

SEK 504.7m

Other Expenses

SEK 111.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 23, 2025
Earnings per share (EPS)
3.54
Gross Margin
74.87%
Net Profit Margin
13.53%
Debt/Equity Ratio
0%

Xvivo Perfusion AB (publ) Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
2 Rewards

About XVIVO

Founded
1998
Employees
193
CEO
Christoffer Rosenblad
WebsiteView website
www.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Swedish Market Performance

  • 7 Days: 2.7%
  • 3 Months: 3.3%
  • 1 Year: -1.2%
  • Year to Date: 3.1%
The market is up 2.7% over the last week, with the Industrials sector leading the way, up 3.2%. As for last year, the market performance has been flat. Looking forward, earnings are forecast to grow by 16% annually. Market details ›